Heart-type fatty acid-binding protein: an overlooked cardiac biomarker

References

• Centers for Disease Control and Prevention, Ambulatory and Hospital Care Statistics Branch. National Hospital Ambulatory Medical CareSurvey: 2016 emergency department summary tables. Available from: https://www.cdc.gov/nchs/data/nhamcs/web_tables/2016_ed_web_tables.pdf.
   Google Scholar
• Schull MJ, Vermeulen MJ, Stukel TA. The risk of missed diagnosis of acute myocardial infarction associated with emergency department volume. Ann Emerg Med. 2006;48(6):647–655.
   PubMed Web of Science ®Google Scholar
• Moy E, Barrett M, Coffey R, et al. Missed diagnoses of acute myocardial infarction in the emergency department: variation by patient and facility characteristics. Diagnosis (Berl)). 2015;2(1):29–40.
   PubMedGoogle Scholar
• Pope HJ, Aufderheide TP, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med. 2000;342(16):1163–1170.
   PubMed Web of Science ®Google Scholar
• Hsia RY, Hale Z, Tabas JA. A national study of the prevalence of life-threatening diagnoses in patients with chest pain. JAMA Intern Med. 2016;176(7):1029–1032.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Technical report series no. 168. Hypertension and coronary heart disease: Classification and criteria for epidemiological studies. [cited 2020 May 25]. Availabel from: http://whqlibdoc.who.int/ trs/WHO_TRS_168.pdf. Published 1959.
   Google Scholar
• Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee f or the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959–969.
   PubMed Web of Science ®Google Scholar
• Tucker JF, Collins RA, Anderson AJ, et al. Early diagnostic efficiency of cardiac troponin I and troponin T for acute myocardial infarction. Acad Emerg Med. 1997;4(1):13–21.
   PubMed Web of Science ®Google Scholar
• Aydin S, Ugur K, Aydin S, et al. Biomarkers in acute myocardial infarction: current perspectives. Vasc Health Risk Manag. 2019;15:1–10.
   PubMed Web of Science ®Google Scholar
• Wang J, Tan GJ, Han LN, et al. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017;14(2):135–150.
   PubMedGoogle Scholar
• Glatz JFC, Van Nieuwenhoven FA, Luiken JJFP, et al. Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids. 1997;57(4–5):373–378.
   PubMed Web of Science ®Google Scholar
• Schaap FG, Van der Vusse GJ, Glatz JFC. Fatty acid-binding proteins in the heart. Mol Cell Biochem. 1998;180(1-2):43–51.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Wakabayashi H, Veerkamp JH, et al. Immunohistochemical distribution of heart-type fatty acid-binding protein immunoreactivity in normal human tissues and in acute myocardial infarct. J Pathol. 1993;170(1):59–65.
   PubMed Web of Science ®Google Scholar
• Zschiesche-Appie Kleine WH, Spitzer Jacques Veerkamp-Jan FC, Glatz EH, et al. Histochemical localization of heart-type fatty-acid binding protein in human and murine tissues. Histochem Cell Biol. 1995;103(2):147–156.
   PubMed Web of Science ®Google Scholar
• Haastrup B, Gill S, Risom Kristensen S, et al. Biochemical markers of ischaemia for the early identification of acute myocardial infarction without ST segment elevation. Vol 94.; 2000. Available from: www.karger.com.
   Google Scholar
• Seino Y, Ogata K. i, Takano T, et al. Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: Comparison with rapid troponin T and myoglobin tests. Am J Med. 2003;115(3):185–190.
   PubMed Web of Science ®Google Scholar
• Seino Y, Tomita Y, Takano T, et al. Office Cardiologists Cooperative Study on whole blood rapid panel tests in patients with suspicious acute myocardial infarction: comparison between heart-type fatty acid-binding protein and troponin T tests. Circ J. 2004;68(2):144–148.
   PubMed Web of Science ®Google Scholar
• Ruzgar O, Bilge AK, Bugra Z, et al. The use of human heart-type fatty acid-binding protein as an early diagnostic biochemical marker of myocardial necrosis in patients with acute coronary syndrome, and its comparison with troponin-T and creatine kinase-myocardial band. Heart Vessels. 2006;21(5):309–314.
   PubMed Web of Science ®Google Scholar
• Cavus U, Coskun F, Yavuz B, et al. Heart-type, fatty-acid binding protein can be a diagnostic marker in acute coronary syndromes. J Natl Med Assoc. 2006;98(7):1067–1070.
   PubMed Web of Science ®Google Scholar
• McCann CJ, Glover BM, Menown IBA, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J. 2008;29(23):2843–2850.
   PubMed Web of Science ®Google Scholar
• Valle HA, Riesgo LGC, Bel MS, et al. Clinical assessment of heart-type fatty acid binding protein in early diagnosis of acute coronary syndrome. Eur J Emerg Med. 2008;15(3):140–144.
   PubMed Web of Science ®Google Scholar
• Orak M, Ustündağ M, Güloğlu C, et al. The role of the heart-type fatty acid binding protein in the early diagnosis of acute coronary syndrome and its comparison with troponin i and creatine kinase-MB isoform. Am J Emerg Med. 2010;28(8):891–896.
   PubMed Web of Science ®Google Scholar
• Haltern G, Peiniger S, Bufe A, et al. Comparison of usefulness of heart-type fatty acid binding protein versus cardiac troponin T for diagnosis of acute myocardial infarction. Am J Cardiol. 2010;105(1):1–9.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kim H, Kim SY, et al. Automated heart-type fatty acid-binding protein assay for the early diagnosis of acute myocardial infarction. Am J Clin Pathol. 2010;134(1):157–162.
   PubMed Web of Science ®Google Scholar
• McMahon CG, Lamont JV, Curtin E, et al. Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med. 2012;30(2):267–274.
   PubMed Web of Science ®Google Scholar
• Garcia-Valdecasas S, Ruiz-Alvarez MJ, De Tena JG, et al. Diagnostic and prognostic value of heart-type fatty acid-binding protein in the early hours of acute myocardial infarction. Acta Cardiol. 2011;66(3):315–321.
   PubMed Web of Science ®Google Scholar
• Aldous S, Pemberton C, Troughton R, et al. Heart fatty acid binding protein and myoglobin do not improve early rule out of acute myocardial infarction when highly sensitive troponin assays are used. Resuscitation. 2012;83(2):e27–e28.
   PubMed Web of Science ®Google Scholar
• Gerede DM, Gülec S, Kiliçkap M, et al. Comparison of a qualitative measurement of heart-type fatty acid-binding protein with other cardiac markers as an early diagnostic marker in the diagnosis of non-ST-segment elevation myocardial infarction. CVJA. 2015;26(6):204–209.
   Google Scholar
• Vupputuri A, Sekhar S, Krishnan S, et al. Heart-type fatty acid-binding protein (H-FABP) as an early diagnostic biomarker in patients with acute chest pain. Indian Heart J. 2015;67(6):538–542.
   PubMedGoogle Scholar
• Inoue K, Suwa S, Ohta H, et al. Heart fatty acid-binding protein offers similar diagnostic performance to high-sensitivity troponin T in emergency room patients presenting with chest pain. Circ J. 2011;75(12):2813–2820.
   PubMed Web of Science ®Google Scholar
• Eggers KM, Venge P, Lindahl B. High-sensitive cardiac troponin T outperforms novel diagnostic biomarkers in patients with acute chest pain. Clin Chim Acta. 2012;413(13-14):1135–1140.
   PubMed Web of Science ®Google Scholar
• Kitamura M, Hata N, Takayama T, et al. High-sensitivity cardiac troponin T for earlier diagnosis of acute myocardial infarction in patients with initially negative troponin T test-comparison between cardiac markers. J Cardiol. 2013;62(6):336–342.
   PubMed Web of Science ®Google Scholar
• Shortt CR, Worster A, Hill SA, et al. Comparison of hs-cTnI, hs-cTnT, hFABP and GPBB for identifying early adverse cardiac events in patients presenting within six hours of chest pain-onset. Clin Chim Acta. 2013;419:39–41.
   PubMed Web of Science ®Google Scholar
• Schoenenberger AW, Stallone F, Walz B, et al. Incremental value of heart-type fatty acid-binding protein in suspected acute myocardial infarction early after symptom onset. Eur Heart J Acute Cardiovasc Care. 2016;5(2):185–192.
   PubMed Web of Science ®Google Scholar
• Bank IE, Dekker MS, Hoes AW, et al. Suspected acute coronary syndrome in the emergency room: Limited added value of heart type fatty acid binding protein point of care or ELISA tests: The FAME-ER (Fatty Acid binding protein in Myocardial infarction Evaluation in the Emergency Room) study. Eur Hear Journal Acute Cardiovasc Care. 2016;5(4):364–374.
   PubMed Web of Science ®Google Scholar
• Gami BN, Patel DS, Haridas N, et al. Utility of heart-type fatty acid binding protein as a new biochemical marker for the early diagnosis of acute coronary syndrome. J Clin Diagn Res. 2015;9(1):BC22–BC24.
   PubMedGoogle Scholar
• Kellens S, Verbrugge FH, Vanmechelen M, et al. Point-of-care heart-type fatty acid binding protein versus high-sensitivity troponin T testing in emergency patients at high risk for acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. 2016;5(2):177–184.
   PubMed Web of Science ®Google Scholar
• Agnello L, Bivona G, Novo G, et al. Heart-type fatty acid binding protein is a sensitive biomarker for early AMI detection in troponin negative patients: a pilot study. Scand J Clin Lab Invest. 2017;77(6):428–432.
   PubMed Web of Science ®Google Scholar
• Bertinchant JP, Larue C, Pernel I, et al. Release kinetics of serum cardiac troponin I in ischemic myocardial injury. Clin Biochem. 1996;29(6):587–594.
   PubMed Web of Science ®Google Scholar
• Kleine AH, Glatz JFC, Van Nieuwenhoven FA, et al. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem. 1992;116(1–2):155–162.
   PubMed Web of Science ®Google Scholar
• Glatz JFC, Renneberg R. Added value of H-FABP as plasma biomarker for the early evaluation of suspected acute coronary syndrome. Clin Lipidol. 2014;9(2):205–220.
   Web of Science ®Google Scholar
• Glatz JFC, van Bilsen M, Paulussen RJA, et al. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. Biochim Biophys Acta (BBA)/Lipids Lipid Metab. 1988;961(1):148–152.
   PubMedGoogle Scholar
• Tanaka T, Hirota Y, Sohmiya K-I, et al. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem. 1991;24(2):195–201.
   PubMed Web of Science ®Google Scholar
• Tsuji R, Tanaka T, Sohmiya K, et al. Human heart-type cytoplasmic fatty acid-binding protein in serum and urine during hyperacute myocardial infarction. Int J Cardiol. 1993;41(3):209–217.
   PubMed Web of Science ®Google Scholar
• Glatz JFC, Van Der Vusse GJ, Simoons ML, et al. Fatty acid-binding protein and the early detection of acute myocardial infarction. Clin Chim Acta. 1998;272(1):87–92.
   PubMed Web of Science ®Google Scholar
• Bruins Slot MHE, Reitsma JB, Rutten FH, et al. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction: a systematic review and meta-analysis. Heart. 2010;96(24):1957–1963.
   PubMed Web of Science ®Google Scholar
• Carroll C, Khalaf MA, Stevens JW, et al. Heart-type fatty acid binding protein as an early marker for myocardial infarction: systematic review and meta-analysis. Emerg Med J. 2013;30(4):280–286.
   PubMed Web of Science ®Google Scholar
• Lippi G, Mattiuzzi C, Cervellin G. Critical review and meta-analysis on the combination of heart-type fatty acid binding protein (H-FABP) and troponin for early diagnosis of acute myocardial infarction. Clin Biochem. 2013;46(1–2):26–30.
   PubMed Web of Science ®Google Scholar
• Trevethan R. Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Heal. 2017; 5(November):1–7.
   PubMed Web of Science ®Google Scholar
• Collinson P, Gaze D, Goodacre S. Comparison of contemporary troponin assays with the novel biomarkers, heart fatty acid binding protein and copeptin, for the early confirmation or exclusion of myocardial infarction in patients presenting to the emergency department with chest pain. Heart. 2014;100(2):140–145.
   PubMed Web of Science ®Google Scholar
• MacGougan CK, Christenson JM, Innes GD, et al. Emergency physicians’ attitudes toward a clinical prediction rule for the identification and earlydischarge of low risk patients with chest discomfort. Can J Emerg Med. 2001;3(02):89–94.
   Google Scholar
• Body R, McDowell G, Carley S, et al. A FABP-ulous 'rule out' strategy? Heart fatty acid binding protein and troponin for rapid exclusion of acute myocardial infarction. Resuscitation. 2011;82(8):1041–1046.
   PubMed Web of Science ®Google Scholar
• Pelsers MMAL, Hermens WT, Glatz JFC. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. 2005;352(1–2):15–35.
   PubMed Web of Science ®Google Scholar
• Wu AHB. Release of cardiac troponin from healthy and damaged myocardium. Front Lab Med. 2017;1(3):144–150
   Google Scholar
• Carlton E, Greenslade J, Cullen L, et al. Evaluation of high-sensitivity cardiac troponin I levels in patients with suspected acute coronary syndrome. JAMA Cardiol. 2016;1(4):405–412.
   PubMed Web of Science ®Google Scholar
• Keller T, Zeller T, Ojeda F, et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA. 2011;306(24):2684–2693.
   PubMed Web of Science ®Google Scholar
• Rubini Giménez M, Hoeller R, Reichlin T, et al. Rapid rule out of acute myocardial infarction using undetectable levels of high-sensitivity cardiac troponin. Int J Cardiol. 2013;168(4):3896–3901.
   PubMed Web of Science ®Google Scholar
• Reiter M, Twerenbold R, Reichlin T, et al. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction. Heart. 2013;99(10):708–714.
   PubMed Web of Science ®Google Scholar
• Liou K, Ho S, Ooi SY. Heart-type fatty acid binding protein in early diagnosis of myocardial infarction in the era of high-sensitivity troponin: a systematic review and meta-analysis. Ann Clin Biochem. 2015;52(3):370–381.
   PubMed Web of Science ®Google Scholar
• Xu LQ, Yang YM, Tong H, et al. Early diagnostic performance of heart-type fatty acid binding protein in suspected acute myocardial infarction: evidence from a meta-analysis of contemporary studies. Hear Lung Circ. 2018;27(4):503–512.
   PubMed Web of Science ®Google Scholar
• Body R, Carley S, McDowell G, et al. The Manchester Acute Coronary Syndromes (MACS) decision rule for suspected cardiac chest pain: derivation and external validation. Heart. 2014;100(18):1462–1468.
   PubMed Web of Science ®Google Scholar
• Carlton E, Body R, Greaves K. External validation of the Manchester Acute Coronary Syndromes decision rule. Acad Emerg Med. 2016;23(2):136–143.
   PubMed Web of Science ®Google Scholar
• Body R, Boachie C, McConnachie A, et al. Feasibility of the Manchester Acute Coronary Syndromes (MACS) decision rule to safely reduce unnecessary hospital admissions: A pilot randomised controlled trial. Emerg Med J. 2017;34(9):586–592.
   PubMed Web of Science ®Google Scholar
• Young JM, Pickering JW, George PM, et al. Heart fatty acid binding protein and cardiac troponin: development of an optimal rule-out strategy for acute myocardial infarction. BMC Emerg Med. 2016;16(1):34.
   PubMedGoogle Scholar
• Van Hise CB, Greenslade JH, Parsonage W, et al. External validation of heart-type fatty acid binding protein, high-sensitivity cardiac troponin, and electrocardiography as rule-out for acute myocardial infarction. Clin Biochem. 2018;52:161–163.
   PubMed Web of Science ®Google Scholar
• Ishii J, Ozaki Y, Lu J, et al. Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem. 2005;51(8):1397–1404.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Hori S, Noma S, et al. Prognostic value of a qualitative test for heart-type fatty acid-binding protein in patients with acute coronary syndrome. Int Heart J. 2005;46(4):601–606.
   PubMed Web of Science ®Google Scholar
• O'Donoghue M, de Lemos JA, Morrow DA, et al. Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes. Circulation. 2006;114(6):550–557.
   PubMed Web of Science ®Google Scholar
• Kilcullen N, Viswanathan K, Das R, et al. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am Coll Cardiol. 2007;50(21):2061–2067.
   PubMed Web of Science ®Google Scholar
• Ilva T, Lund J, Porela P, et al. Early markers of myocardial injury: cTnI is enough. Clin Chim Acta. 2009;400(1-2):82–85.
   PubMed Web of Science ®Google Scholar
• McCann CJ, Glover BM, Menown IBA, et al. Prognostic value of a multimarker approach for patients presenting to hospital with acute chest pain. Am J Cardiol. 2009;103(1):22–28.
   PubMed Web of Science ®Google Scholar
• Viswanathan K, Kilcullen N, Morrell C, et al. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. J Am Coll Cardiol. 2010;55(23):2590–2598.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 ;37(27):2129–2200.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803.
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107(9):1278–1283.
   PubMed Web of Science ®Google Scholar
• Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105(20):2392–2397.
   PubMed Web of Science ®Google Scholar
• Kociol RD, Horton JR, Fonarow GC, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail. 2011;4(5):628–636.
   PubMed Web of Science ®Google Scholar
• Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43(4):635–641.
   PubMed Web of Science ®Google Scholar
• Verdiani V, Ognibene A, Rutili MS, et al. NT-ProBNP reduction percentage during hospital stay predicts long-term mortality and readmission in heart failure patients. J Cardiovasc Med. 2008;9:694–699.
   Google Scholar
• Huelsmann M, Neuhold S, Resl M, et al. PONTIAC (NT-proBNP selected prevention of cardiac eveNts in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62(15):1365–1372.
   PubMed Web of Science ®Google Scholar
• Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP-HF randomized trial. Vol 310; 2013. Available from: https://jamanetwork.com/.
   Google Scholar
• Hoffmann U, Espeter F, Weiß C, et al. Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure – diagnostic and prognostic insights compared to NT-proBNP and troponin I. BMC Cardiovasc Disord. 2015;15(1):50.
   PubMedGoogle Scholar
• Lichtenauer M, Jirak P, Wernly B, et al. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. Eur J Intern Med. 2017;44:31–38.
   PubMed Web of Science ®Google Scholar
• Setsuta K, Seino Y, Ogawa T, et al. Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am Jourmal Med. 2002;113(9):717–722.
   PubMed Web of Science ®Google Scholar
• Arimoto T, Takeishi Y, Shiga R, et al. Prognostic value of elevated circulating heart-type fatty acid binding protein in patients with congestive heart failure. J Card Fail. 2005;11(1):56–60.
   PubMed Web of Science ®Google Scholar
• Niizeki T, Takeishi Y, Arimoto T, et al. Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. Circ J. 2005;69:922–927.
   Google Scholar
• Komamura K, Sasaki T, Hanatani A, et al. Heart-type fatty acid binding protein is a novel prognostic marker in patients with non-ischaemic dilated cardiomyopathy. Heart. 2006;92(5):615–618.
   PubMed Web of Science ®Google Scholar
• Niizeki T, Takeishi Y, Arimoto T, et al. Heart-type fatty acid-binding protein is more sensitive than troponin t to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail. 2007;13(2):120–127.
   PubMed Web of Science ®Google Scholar
• Niizeki T, Takeishi Y, Arimoto T, et al. Persistently increased serum concentration of heart-type fatty acid-binding protein predicts adverse clinical outcomes in patients with chronic heart failure. Circ J. 2008;72(1):109–114.
   PubMed Web of Science ®Google Scholar
• Setsuta K, Seino Y, Kitahara Y, et al. Elevated levels of both cardiomyocyte membrane and myofibril damage markers predict adverse outcomes in patients with chronic heart failure. Circ J. 2007;72(4):569–574.
   Web of Science ®Google Scholar
• Kutsuzawa D, Arimoto T, Watanabe T, et al. Ongoing myocardial damage in patients with heart failure and preserved ejection fraction. J Cardiol. 2012;60(6):454–461.
   PubMed Web of Science ®Google Scholar
• Otaki Y, Arimoto T, Takahashi H, et al. Prognostic value of myocardial damage markers in patients with chronic heart failure with atrial fibrillation. Intern Med. 2014;53(7):661–668.
   PubMed Web of Science ®Google Scholar
• Shirakabe A, Hata N, Kobayashi N, et al. Serum heart-type fatty acid-binding protein level can be used to detect acute kidney injury on admission and predict an adverse outcome in patients with acute heart failure. Circ J. 2015;79(1):119–128.
   PubMed Web of Science ®Google Scholar
• Kadowaki S, Watanabe T, Otaki Y, et al. Combined assessment of myocardial damage and electrical disturbance in chronic heart failure. World J Cardiol. 2017;9(5):396–469.
   PubMed Web of Science ®Google Scholar
• Kazimierczyk E, Kazimierczyk R, Harasim-Symbor E, et al. Persistently elevated plasma heart-type fatty acid binding protein concentration is related with poor outcome in acute decompensated heart failure patients. Clin Chim Acta. 2018;487:48–53.
   PubMed Web of Science ®Google Scholar
• Dinh W, Nickl W, Füth R, et al. High sensitive troponin T and heart fatty acid binding protein: Novel biomarker in heart failure with normal ejection fraction?: a cross-sectional study. BMC Cardiovasc Disord. 2011;11(1):41.
   Google Scholar
• Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry J Am Coll Cardiol 1997;30:165–171.
   Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J.  2020;41(4):543-603.
   Google Scholar
• Barco S, Mahmoudpor SH, Planquette B, et al. Assessing the severity of acute pulmonary embolism: back to the future?. Eur Heart J. 2019;40(11):911–913.
   PubMed Web of Science ®Google Scholar
• Kucher N, Rossi E, De Rosa M, et al. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 Mm Hg or higher. Arch Intern Med. 2005;165:1777–1781.
   Google Scholar
• Kaczyñska A, Pelsers MMAL, Bochowicz A, et al. Plasma heart-type fatty acid binding protein is superior to troponin and myoglobin for rapid risk stratification in acute pulmonary embolism. Clin Chim Acta. 2006;371(1–2):117–123.
   PubMed Web of Science ®Google Scholar
• Puls M, Dellas C, Lankeit M, et al. Heart-type fatty acid-binding proteins (H-FABP): A reliable tool for initial risk stratification of pulmonary embolism?. Eur Heart J. 2007;28(2):146–147.
   PubMed Web of Science ®Google Scholar
• Boscheri A, Wunderlich C, Langer M, et al. Correlation of heart-type fatty acid-binding protein with mortality and echocardiographic data in patients with pulmonary embolism at intermediate risk. Am Heart J. 2010;160(2):294–300.
   PubMed Web of Science ®Google Scholar
• Dellas C, Puls M, Lankeit M, et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol. 2010;55(19):2150–2157.
   PubMed Web of Science ®Google Scholar
• Gül EE, Can I, Güler I, et al. Association of pulmonary artery obstruction index with elevated heart-type fatty acid binding protein and short-term mortality in patients with pulmonary embolism at intermediate risk. Diagn Interv Radiol. 2012;18(6):531–536.
   PubMed Web of Science ®Google Scholar
• Lankeit M, Dellas C, Benz V, et al. The predictive value of heart-type fatty acid-binding protein is independent from symptom duration in normotensive patients with pulmonary embolism. Thromb Res. 2013;132(5):543–547.
   PubMed Web of Science ®Google Scholar
• Gul EE, Can I, Kayrak M, et al. Thrombolysis in patients with pulmonary embolism and elevated heart-type fatty acid-binding protein levels. J Thromb Thrombolysis. 2014;37(4):483–489.
   PubMed Web of Science ®Google Scholar
• Langer M, Forkmann M, Richter U, et al. Heart-type fatty acid-binding protein and myocardial creatine kinase enable rapid risk stratification in normotensive patients with pulmonary embolism. J Crit Care. 2016;35:174–179.
   PubMed Web of Science ®Google Scholar
• Dellas C, Lobo JL, Rivas A, et al. Risk stratification of acute pulmonary embolism based on clinical parameters, H-FABP and multidetector CT. Int J Cardiol. 2018;265:223–228.
   PubMed Web of Science ®Google Scholar
• Bajaj A, Rathor P, Sehgal V, et al. Risk stratification in acute pulmonary embolism with heart-type fatty acid-binding protein: a meta-analysis. J Crit Care. 2015;30(5):1151.e1–e7.
   Web of Science ®Google Scholar
• Fransen EJ, Maessen JG, Hermens WT, et al. Demonstration of ischemia-reperfusion injury separate from postoperative infarction in coronary artery bypass graft patients. Ann Thorac Surg. 1998;65:48–53.
   Google Scholar
• Thielmann M, Pasa S, Holst T, et al. Heart-type fatty acid binding protein and ischemia-modified albumin for detection of myocardial infarction after coronary artery bypass graft surgery. Ann Thorac Surg. 2017;104(1):130–137.
   PubMed Web of Science ®Google Scholar
• Hayashida N, Chihara S, Akasu K, et al. Plasma and urinary levels of heart fatty acid-binding protein in patients undergoing cardiac surgery. Jpn Circ J. 2000;64(1):18–20.
   PubMedGoogle Scholar
• Muehlschlegel JD, Perry TE, Liu KY, et al. Heart-type fatty acid binding protein is an independent predictor of death and ventricular dysfunction after coronary artery bypass graft surgery. Anesth Analg. 2010;111(5):1101–1109.
   PubMed Web of Science ®Google Scholar
• Zimmermann-Ivol CG, Burkhard PR, Le Floch-Rohr J, et al. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics. 2004;3(1):66–72.
   PubMed Web of Science ®Google Scholar
• Wunderlich MT, Hanhoff T, Goertler M, et al. Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol. 2005;252(6):718–724.
   PubMed Web of Science ®Google Scholar
• Park SY, Kim MH, Kim OJ, et al. Plasma heart-type fatty acid binding protein level in acute ischemic stroke: Comparative analysis with plasma S100B level for diagnosis of stroke and prediction of long-term clinical outcome. Clin Neurol Neurosurg. 2013;115(4):405–410.
   PubMed Web of Science ®Google Scholar
• Park SY, Kim J, Kim OJ, et al. Predictive value of circulating interleukin-6 and heart-type fatty acid binding protein for three months clinical outcome in acute cerebral infarction: multiple blood markers profiling study. Crit Care. 2013;17(2):R45.
   PubMed Web of Science ®Google Scholar
• Dolmans LS, Rutten FH, Koenen NCT, et al. Candidate biomarkers for the diagnosis of transient ischemic attack: a systematic review. Cerebrovasc Dis. 2019;47(5–6):207–216.
   PubMed Web of Science ®Google Scholar
• Borg J, Holm L, Cassidy JD, et al. Diagnostic procedures in mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med Suppl. 2004; 36:61–75.
   Web of Science ®Google Scholar
• Melnick ER, Szlezak CM, Bentley SK, et al. CT overuse for mild traumatic brain injury. Jt Comm J Qual Patient Saf. 2012;38(11):483–489.
   PubMedGoogle Scholar
• Sharma R, Rosenberg A, Bennett ER, et al. A blood-based biomarker panel to risk-stratify mild traumatic brain injury. PLOS One. 2017;12(3):e0173798.
   PubMed Web of Science ®Google Scholar
• Lagerstedt L, Egea-Guerrero JJ, Bustamante A, et al. H-FABP: a new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLOS One. 2017;12(4):e0175572.
   PubMed Web of Science ®Google Scholar
• Posti JP, Takala RSK, Lagerstedt L, et al. Correlation of blood biomarkers and biomarker panels with traumatic findings on computed tomography after traumatic brain injury. J Neurotrauma. 2019;36(14):2178–2189.
   PubMed Web of Science ®Google Scholar
• Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARSCoV-2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524.
   PubMed Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. JAMA Cardiol. 2020;5(7):802.
   PubMed Web of Science ®Google Scholar
• Yin L, Mou H, Shao J, et al. Correlation between heart fatty acid binding protein and severe COVID-19: a case-control study. PLOS One. 2020;15(4):e0231687.
   PubMed Web of Science ®Google Scholar